Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Discovery channel feed
Ron Evans steals a trick from I/O, and points the way to a transformational diabetes therapy
5 years ago
Takeda maps out a discovery alliance aimed at breaking through the safety and efficacy boundaries that limit the first-gen gene therapies
5 years ago
Financing
R&D
Sekar Kathiresan showcases historic monkey data in hunt for a once-and-done gene editing approach to prevent heart attacks
5 years ago
Cell/Gene Tx
Back to the immunology drawing board, AbbVie inks discovery deal with old Allergan partner
5 years ago
Deals
Burned by Alzheimer’s failures, a cautious Merck turns to a startup biotech for some preclinical neuro programs
5 years ago
Deals
R&D
Nimbus picks 4 preclinical targets for the next chapter of its pioneering computational drug discovery work
5 years ago
Spark touts animal data for a solution to AAV gene therapy's antibody problem
5 years ago
Cell/Gene Tx
A UCSD center that's been facilitating Covid-19 clinical research gets $55M from NIH to boost translational work
6 years ago
R&D
The newest, $86M Third Rock startup chases the tiny biological machines inside of you
6 years ago
Financing
Startups
Joining Novartis in siRNA space, AstraZeneca hands Silence $80M upfront for discovery deal
6 years ago
Deals
How to build CAR–M: Carl June protégé and his biotech publish first evidence in Nature Biotechnology
6 years ago
People
Cell/Gene Tx
Astellas empowers newly energized CytomX with $80M upfront to get preclinical bispecific work going
6 years ago
Deals
Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach
6 years ago
'Dramatic times': How did an $8B surge in NIH grants over five years change research on the ground (if at all)?
6 years ago
In Focus
Microbiome Q&A: New study maps the vagina's 'optimal microbiota' — and its implications for biopharma
6 years ago
Tying basic science to spinouts, Dana-Farber debuts sister funds totaling $126M with MPM Capital
6 years ago
Financing
Scientists find unexpected anti-cancer activity in range of non-oncology drugs — study
6 years ago
R&D
How pancreatic RAS tumors protect themselves. Researchers point to a new protein — and maybe a new treatment
6 years ago
R&D
HHMI discriminated against two Asian American women investigators, lawsuits allege
6 years ago
People
NIH-directed purge of researchers with China ties sweeps up Moffitt CEO Alan List, colleagues
6 years ago
China
Pfizer's retired NASH drug shown to reduce liver fat, inspiring new faith in the DGAT2 pathway
6 years ago
Mass General team presents mouse data to back the case for using reformulated asthma drug to treat ALS
6 years ago
Compound nestled in parasitic worm offers promise as antibiotic against obstinate superbugs
6 years ago
Here's a $25M seed fund aimed at backing some brash new drug ideas out of the Broad
6 years ago
Financing
First page
Previous page
3
4
5
6
7
8
9
Next page
Last page